azithromycin + montelukast

azithromycin + montelukast is a combination of two distinct pharmaceutical drugs: azithromycin, a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and montelukast, a leukotriene receptor antagonist that blocks cysteinyl leukotriene receptor type 1 (CysLT1), reducing inflammation and bronchoconstriction. This combination has been studied for improved lung function and reduction of inflammatory markers in pediatric respiratory diseases such as *Mycoplasma pneumoniae* pneumonia, without increasing adverse events. Its use is also explored in broader airway diseases but is not an established or widely approved fixed-dose combination[2][5].